Abstracts

Assessment of Hepatic Antifibrotic Effect of Cenicriviroc in Patients With HIV

Chronic liver disease is frequently observed in HIV-infected patients and is multifactorial. Attenuation of fibrotic progression may improve liver-related morbidity and mortality. Cenicriviroc (CVC) is an oral, dual antagonist of CCR2/CCR5, which are involved in key pro-inflammatory and fibrogenic pathways. We evaluated effects of 2 doses of CVC on serum hepatic fibrosis biomarkers in HIV+…

Impact of PNPLA3 Variants on the Liver Histology of 168 HIV/HCV Patients

A genome-wide association study recently identified a non-synonymous sequence variation (rs738409 C to G) encoding an isoleucine-to-methionine substitution at position 148 in the adiponutrin/patatin-like phospholipase-3 (PNPLA3) gene, which appears to be the strongest determinant of human steatosis.The I148M variant of PNPLA3 has been found to be independently associated with liver steatosis and disease progression in…

MiR-122 and -200a in Exosomes of ART+ HIV-1 Infected Individuals With Liver Disease

Liver disease is one of the main contributors to the increased levels of morbidity and mortality seen in the HIV-1 infected, ART-treated population. Circulating miRNAs, particularly those located inside exosomes, are seen as promising biomarkers for a number of human disease conditions including liver related diseases. Furthermore miRNAs carried in exosomes, as distinct from those…

Atherosclerotic Myocardial Infarction Risk in the NA-ACCORD Compared to MESA and ARIC

HIV-infected individuals are likely at increased risk of myocardial infarction (MI) compared to uninfected individuals. However, identifying a comparable uninfected group is difficult because of differences in cardiovascular disease (CVD) risk factors. The Multi-Ethnic Study of Atherosclerosis (MESA) and the Atherosclerosis Risk in Communities (ARIC) are large, diverse general population cohorts designed to assess CVD…

Differences by HIV Serostatus in Coronary Artery Disease Following Stress Testing

HIV-infected persons develop coronary artery disease (CAD) more commonly and earlier than uninfected patients. The role of noninvasive cardiovascular testing to stratify CAD risk in this population is not well-defined; no prior studies have evaluated cardiovascular stress testing in this group.  We hypothesized that, among persons with abnormal stress tests, HIV-infected patients have a greater…